Published in Cancer Weekly, February 15th, 2005
"ErbB2 is a transmembrane tyrosine kinase whose surface overexpression is linked to tumorigenesis and poor prognosis in breast cancer patients," scientists in California explained. "Two models have emerged that account for the high surface distribution of ErbB2."
"In one model, the surface pool is dynamic and governed by a balance between endocytosis and recycling, whereas in the other it is retained, static, and excluded from endocytosis," according to C.D. Austin and colleagues at Genentech, Inc. in San Francisco. "These models have contrasting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.